Skip to main content
. 2020 May 15;20:65. doi: 10.1186/s12902-020-00549-w

Table 2.

The relationship of glycemic control for HbA1c and blood glucose in T2DM subjects

HbA1c Glucose
Median (IQR) P-value Median (IQR) P-value
Hypertension-No 7.7 (6.7–9.4) 0.730 8.9 (6.6–12.8) 0.023
Hypertension-Yes 8.0 (6.7–9.3) 7.8 (6.1–10.6)
Dyslipidemia-No 7.7 (6.6–9.2) 0.360 8.5 (6.3–13.1) 0.419
Dyslipidemia-Yes 8.0 (6.8–9.4) 8.2 (6.2–10.7)
Retinopathy-No 7.4 (6.6–9.1) 0.001 8.1 (6.3–10.7) 0.599
Retinopathy-Yes 8.6 (7.3–9.8) 8.6 (6.2–10.9)
Neuropathy-No 7.8 (6.7–9.2) 0.119 8.2 (6.2–10.8) 0.325
Neuropathy-Yes 8.2 (7.2–9.7) 8.5 (6.7–11.3)
PAD-No 7.9 (6.7–9.3) 0.970 8.3 (6.2–10.8) 0.757
PAD-Yes 7.3 (6.7–9.7) 7.8 (7.2–14.9)
CAD-No 7.8 (6.7–9.3) 0.287 8.4 (6.3–10.9) 0.645
CAD-Yes 8.1 (6.9–9.9) 8.1 (6.2–9.5)
Stroke-No 7.8 (6.7–9.3) 0.297 8.3 (6.1–10.9) 0.576
Stroke-Yes 8.8 (6.9–9.8) 8.5 (7.1–10.9)

PAD Peripheral artery disease, CAD coronary artery disease